2,3-二氯苯硼酸 | 151169-74-3

• 物质功能分类: 化学试剂 - 有机试剂 - 硼酸
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2,3-二氯苯硼酸
• 中文别名: 2,3-二氯苯基硼酸；2.3-二氯苯硼酸
• 英文名称: 2,3-dichlorobenzeneboronic acid
• 英文别名: 2,3-dichloro-phenylboronic acid；2,3-Dichlorophenylboronic acid；(2,3-dichlorophenyl)boronic acid
• CAS: 151169-74-3
• 化学式: C₆H₅BCl₂O₂
• mdl: MFCD01075703
• 分子量: 190.821
• InChiKey: TYIKXPOMOYDGCS-UHFFFAOYSA-N

物化性质

• 熔点：
  125 °C (dec.) (lit.)
• 沸点：
  349.8±52.0 °C(Predicted)
• 密度：
  1.47±0.1 g/cm3(Predicted)
• 溶解度：
  溶于甲醇。
• 稳定性/保质期：
  在常温常压下保持稳定，应避免与强氧化剂接触。

计算性质

• 辛醇/水分配系数(LogP)：
  2.68
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  40.5
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xn
• 安全说明：
  S26,S37/39
• 危险类别码：
  R22,R36/37/38
• WGK Germany：
  3
• 海关编码：
  2931900090
• 危险品运输编号：
  NONH for all modes of transport
• 危险类别：
  IRRITANT
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  密封储存，应存放于阴凉干燥的库房中。

SDS

Name:	2 3-Dichlorophenylboronic acid Material Safety Data Sheet
Synonym:	None Known
CAS:	151169-74-3

Section 1 - Chemical Product MSDS Name:2 3-Dichlorophenylboronic acid Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
151169-74-3	2,3-Dichlorophenylboronic acid	97	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation. May cause chemical conjunctivitis.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled. Can produce delayed pulmonary edema.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid. Do NOT use mouth-to-mouth resuscitation.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Minimize dust generation and accumulation. Avoid breathing dust, vapor, mist, or gas. Avoid contact with eyes, skin, and clothing.
Keep container tightly closed. Avoid ingestion and inhalation. Use with adequate ventilation. Wash clothing before reuse.
Storage:
Store in a tightly closed container. Store in a dry area. Keep refrigerated. (Store below 4C/39F.)

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 151169-74-3: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Powder
Color: white to off-white
Odor: odorless
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 242 - 244 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C6H5BCl2O2
Molecular Weight: 190.82

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable at room temperature in closed containers under normal storage and handling conditions.
Conditions to Avoid:
Dust generation.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Hydrogen chloride, carbon monoxide, carbon dioxide, boron oxides.
Hazardous Polymerization: Will not occur.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 151169-74-3 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
2,3-Dichlorophenylboronic acid - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 151169-74-3: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 151169-74-3 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 151169-74-3 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

用途

2,3-二氯苯硼酸中的硼酸单元可以与芳基卤化物进行Suzuki偶联反应，生成相应的芳基化产物；此外，该单元还可以通过氧化反应转化为相应的苯酚类化合物，并在氟氢化钾的作用下转变为活性更高的三氟硼酸钾盐。

制备

将2,3-二氯溴苯（24.0 mmol，1.00当量）溶解于干燥的四氢呋喃（31毫升，约0.7毫升）中，并冷却至-78℃。随后，在此条件下滴加正丁基锂（32.1 mmol，1.10当量）。反应混合物在-78℃下搅拌2小时后，通过注射器加入硼酸三甲酯（2.1当量），并将溶液温热至室温进行过夜反应。完成后，使用冰浴冷却悬浮液，并向体系中滴加盐酸（1 M，40毫升）。混合物在室温下继续搅拌2小时后，分去两相，用乙醚（3×20毫升）萃取水相。合并有机层并用水（3×15毫升）清洗，然后用Na2SO4干燥。过滤除去干燥剂并在真空中浓缩除去溶剂，即可得到目标产物分子——2,3-二氯苯硼酸。

反应信息

• 作为反应物：
  描述：

  2,3-二氯苯硼酸 在 六氟异丙醇 、 N-nitrosaccharin 作用下， 反应 19.0h， 以96%的产率得到2,3-二氯硝基苯
  参考文献：
  名称：

  N-硝基杂环：用于芳基和杂芳基硼酸的催化Ipso硝化的稳定型有机试剂。

  摘要：

  光催化与通过不含金属的协议来访问各种芳族和杂芳族硝基化合物本位基于非金属使用被开发容易得到的硼酸衍生物的-nitration，长凳稳定的，并可回收硝化试剂。这些方法操作简便，温和，区域选择性，并且具有出色的官能团相容性，可提供高达99％的收率的所需产品。

  DOI：

  10.1021/acs.orglett.0c00671
• 作为产物：
  描述：

  硼酸三甲酯 、 2,3-二氯溴苯 在 正丁基锂 作用下， 以 四氢呋喃 、 正己烷 、 水 、 Petroleum ether 为溶剂， 以8.42 g (50%)的产率得到2,3-二氯苯硼酸
  参考文献：
  名称：

  Pyrazine compounds

  摘要：

  式（I）的化合物，其中R1选自苯基，该苯基被一个或多个卤素原子取代，萘基和该萘基被一个或多个卤素原子取代的基团；R2选自—NH2和—NHC(═O)Ra的基团；R3选自—NRbRc，—NHC(═O)Ra和氢的基团；R4选自氢，-C1-4烷基，-C1-4烷基被一个或多个卤素原子取代，—CN，—CH2OH，—CH2ORd和—CH2S(O)xRd的基团；其中Ra代表C1-4烷基或C3-7环烷基，Rb和Rc（可以相同也可以不同）选自氢和C1-4烷基，或者与它们连接的氮原子一起形成一个含氮的6元杂环，该杂环可以进一步用一个或多个C1-4烷基取代；Rd选自C1-4烷基或C1-4烷基被一个或多个卤素原子取代；x是整数零、一或二；以及其药学上可接受的衍生物；但是R1不代表（a）；当R2为—NH2且R3和R4均为氢时。

  公开号：

  US06255307B1

文献信息

• PYRIMIDINE-FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF
  申请人：SHANGHAI BLUERAY BIOPHARMA CO., LTD.

  公开号：US20210053989A1

  公开（公告）日：2021-02-25

  Disclosed in the present disclosure are a pyrimidine-fused cyclic compound or a pharmaceutically acceptable salt, hydrate, prodrug, stereoisomer, solvate or isotope labeled compound thereof. Also provided in the present disclosure are a preparation method for the compound, a composition comprising the compound and a use of the compound for the preparation of a medicament for the prevention and/or treatment of a disease or condition associated with abnormal SHP2 activity.

  本公开涉及一种嘧啶融合的环状化合物或其药用可接受的盐、水合物、前药、立体异构体、溶剂合物或同位素标记化合物。本公开还提供了该化合物的制备方法、包含该化合物的组合物以及该化合物用于制备与异常SHP2活性相关的疾病或病况的药物的用途。
• [EN] COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2<br/>[FR] COMPOSÉS ET COMPOSITIONS POUR INHIBER L'ACTIVITÉ DE SHP2
  申请人：NOVARTIS AG

  公开号：WO2016203404A1

  公开（公告）日：2016-12-22

  The present invention relates to compounds of formula I. The compounds are inhibitors of the Src Homolgy-2 phosphatase (SHP2) and thus useful in the treatment of Noonan Syndrome, Leopard Syndrome and cancer.

  本发明涉及式I的化合物。这些化合物是Src同源-2磷酸酶（SHP2）的抑制剂，因此在努南综合征、豹纹综合征和癌症的治疗中有用。
• Process for preparation of benzo[f]quinolinones
  申请人：Eli Lilly and Company

  公开号：US05578724A1

  公开（公告）日：1996-11-26

  A series of benzoquinolin-3-ones are pharmaceuticals effective in treating conditions consequent on both Type I and Type II 5.alpha.-reductase and their preparation is disclosed.

  一系列苯醌啉-3-酮类药物在治疗由I型和II型5α-还原酶引起的疾病方面具有有效性，并且其制备方法已被披露。
• 一种嘧啶类化合物及其制备方法和应用
  申请人：中国科学院广州生物医药与健康研究院

  公开号：CN106928192B

  公开（公告）日：2020-11-13

  本发明公开了一种嘧啶类化合物，结构如式(I)所示：式中，R1选自氢、卤素、硝基、氰基、羟基、氨基、二甲氨基、Cl‑6烷基、Cl‑6全氟烷基、C2‑6烯基、C2‑6炔基、C3‑6环烷基、C3‑12杂脂环基或Cl‑6烷氧基中的一种；R2选自氢、Cl‑6烷基、C2‑6烯基、C2‑6炔基、C3‑6环烷基、C3‑6环烷氧基、C3‑12杂脂环基、芳基、取代芳基或基团P中的一种，P基团为R3选自氢或基团Q，基团Q为其中，X选自O、S、NH或‑NHCO‑中的一种；基团P和基团Q至少出现一个；m为1‑7；n为1‑7。本发明所涉及的嘧啶类化合物是8‑羟基鸟嘌呤核苷酸酶抑制剂，可用于治疗因8‑羟基鸟嘌呤核苷酸酶活性异常所引起的疾病，例如肿瘤。
• BISARYL-BONDED ARYLTRIAZOLONES AND USE THEREOF
  申请人：Furstner Chantal

  公开号：US20130190330A1

  公开（公告）日：2013-07-25

  The present application relates to novel bisaryl-linked 5-aryl-1,2,4-triazolone derivatives, to processes for preparing them, to their use alone or in combinations for the treatment and/or prevention of diseases and also to their use for the production of medicaments for the treatment and/or prevention of diseases, more particularly for the treatment and/or prevention of cardiovascular disorders.

  本申请涉及新型的双芳基连接的5-芳基-1,2,4-三唑啉酮衍生物，涉及制备它们的方法，涉及它们单独或组合用于治疗和/或预防疾病，以及涉及它们用于生产用于治疗和/或预防疾病的药物，尤其是用于治疗和/或预防心血管疾病的药物。